Table 2 Clinicopathologic variables and NUCB2 protein expression in 180 PCa patients
From: Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer
Variable | Group | NUCB2 protein expression | P value | ||
|---|---|---|---|---|---|
n | High | Low | |||
Age | 0.897 | ||||
<70 | 97 | 54 (55.7%) | 43 (44.3%) | ||
≥70 | 83 | 47 (56.6%) | 36 (43.4%) | ||
Lymph node metastasis | 0.022 | ||||
Positive | 17 | 14 (82.4%) | 3 (17.6%) | ||
Negtive | 163 | 87 (53.4%) | 76 (46.6%) | ||
Surgical margin status | 0.521 | ||||
Positive | 14 | 9 (64.3%) | 5 (35.7%) | ||
Negtive | 166 | 92 (55.4%) | 74 (44.6%) | ||
Seminal vesicle invasion | 0.016 | ||||
Positive | 35 | 26 (74.3%) | 9 (25.7%) | ||
Negtive | 145 | 75 (51.8%) | 70 (48.3%) | ||
PCa stage | 0.114 | ||||
T1 | 103 | 63 (61.2%) | 40 (38.8%) | ||
T2/T3 | 77 | 38 (49.4%) | 39 (50.6%) | ||
Preoperative PSA | 0.006 | ||||
<4 | 5 | 1 (20%) | 4 (80%) | ||
4-10 | 64 | 28 (43.8%) | 36 (56.2%) | ||
>10 | 111 | 72 (64.9%) | 39 (35.1%) | ||
Gleason score | 0.017 | ||||
<7 | 99 | 47 (47.5%) | 52 (52.5%) | ||
7 | 34 | 20 (58.8%) | 14 (41.2%) | ||
>7 | 47 | 34 (72.3%) | 13 (27.7%) | ||
Angiolymphatic invasion | 0.042 | ||||
Positive | 35 | 25 (71.4%) | 10 (28.6%) | ||
Negtive | 145 | 76 (52.4%) | 69 (47.6%) | ||
Biochemical recurrence | 0.003 | ||||
Absence | 128 | 63 (49.2%) | 65 (50.8%) | ||
Presence | 52 | 38 (73.1%) | 14 (26.9%) | ||